<?xml version="1.0" encoding="UTF-8"?>

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="cdsi-observation-codes"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem cdsi-observation-codes</b></p><a name="cdsi-observation-codes"> </a><a name="hccdsi-observation-codes"> </a><p>This  code system <code>http://fhirfli.dev/fhir/ig/cicada/CodeSystem/cdsi-observation-codes</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">001<a name="cdsi-observation-codes-001"> </a></td><td>Patient seeks protection</td></tr><tr><td style="white-space:nowrap">002<a name="cdsi-observation-codes-002"> </a></td><td>Undergoing elective splenectomy</td></tr><tr><td style="white-space:nowrap">003<a name="cdsi-observation-codes-003"> </a></td><td>Immunocompromised</td></tr><tr><td style="white-space:nowrap">004<a name="cdsi-observation-codes-004"> </a></td><td>Recipient of a hematopoietic stem cell transplant</td></tr><tr><td style="white-space:nowrap">005<a name="cdsi-observation-codes-005"> </a></td><td>Hepatitis C virus infection</td></tr><tr><td style="white-space:nowrap">006<a name="cdsi-observation-codes-006"> </a></td><td>Receives clotting factor concentrates</td></tr><tr><td style="white-space:nowrap">007<a name="cdsi-observation-codes-007"> </a></td><td>Pregnant</td></tr><tr><td style="white-space:nowrap">008<a name="cdsi-observation-codes-008"> </a></td><td>Travel to an area of active cholera transmission</td></tr><tr><td style="white-space:nowrap">009<a name="cdsi-observation-codes-009"> </a></td><td>Breastfeeding</td></tr><tr><td style="white-space:nowrap">010<a name="cdsi-observation-codes-010"> </a></td><td>Cerebrospinal fluid leaks</td></tr><tr><td style="white-space:nowrap">011<a name="cdsi-observation-codes-011"> </a></td><td>Cochlear implants</td></tr><tr><td style="white-space:nowrap">012<a name="cdsi-observation-codes-012"> </a></td><td>Family history of altered immunocompetence</td></tr><tr><td style="white-space:nowrap">013<a name="cdsi-observation-codes-013"> </a></td><td>Severe Combined Immunodeficiency [SCID]</td></tr><tr><td style="white-space:nowrap">014<a name="cdsi-observation-codes-014"> </a></td><td>Diabetes</td></tr><tr><td style="white-space:nowrap">015<a name="cdsi-observation-codes-015"> </a></td><td>Chronic liver disease</td></tr><tr><td style="white-space:nowrap">016<a name="cdsi-observation-codes-016"> </a></td><td>Chronic heart disease</td></tr><tr><td style="white-space:nowrap">017<a name="cdsi-observation-codes-017"> </a></td><td>Chronic lung disease</td></tr><tr><td style="white-space:nowrap">018<a name="cdsi-observation-codes-018"> </a></td><td>Laboratory Evidence of Immunity or confirmation of Hepatitis A disease</td></tr><tr><td style="white-space:nowrap">019<a name="cdsi-observation-codes-019"> </a></td><td>Laboratory Evidence of Immunity or confirmation of Hepatitis B disease</td></tr><tr><td style="white-space:nowrap">020<a name="cdsi-observation-codes-020"> </a></td><td>Laboratory Evidence of Immunity for Measles</td></tr><tr><td style="white-space:nowrap">021<a name="cdsi-observation-codes-021"> </a></td><td>Laboratory Evidence of Immunity for Mumps</td></tr><tr><td style="white-space:nowrap">022<a name="cdsi-observation-codes-022"> </a></td><td>Laboratory Evidence of Immunity for Rubella</td></tr><tr><td style="white-space:nowrap">023<a name="cdsi-observation-codes-023"> </a></td><td>Laboratory Evidence of Immunity or confirmation of Varicella disease</td></tr><tr><td style="white-space:nowrap">024<a name="cdsi-observation-codes-024"> </a></td><td>Healthcare provider verified history of or diagnosis of Varicella</td></tr><tr><td style="white-space:nowrap">025<a name="cdsi-observation-codes-025"> </a></td><td>Healthcare provider verified history or diagnosis of Herpes Zoster</td></tr><tr><td style="white-space:nowrap">026<a name="cdsi-observation-codes-026"> </a></td><td>Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]</td></tr><tr><td style="white-space:nowrap">027<a name="cdsi-observation-codes-027"> </a></td><td>Asthma</td></tr><tr><td style="white-space:nowrap">028<a name="cdsi-observation-codes-028"> </a></td><td>Intussusception</td></tr><tr><td style="white-space:nowrap">029<a name="cdsi-observation-codes-029"> </a></td><td>Acute gastroenteritis</td></tr><tr><td style="white-space:nowrap">030<a name="cdsi-observation-codes-030"> </a></td><td>Acute febrile illness</td></tr><tr><td style="white-space:nowrap">031<a name="cdsi-observation-codes-031"> </a></td><td>Tuberculosis</td></tr><tr><td style="white-space:nowrap">032<a name="cdsi-observation-codes-032"> </a></td><td>Dialysis patient</td></tr><tr><td style="white-space:nowrap">033<a name="cdsi-observation-codes-033"> </a></td><td>Taken influenza antiviral medications within the previous 48 hours</td></tr><tr><td style="white-space:nowrap">034<a name="cdsi-observation-codes-034"> </a></td><td>Receiving long-term aspirin therapy</td></tr><tr><td style="white-space:nowrap">035<a name="cdsi-observation-codes-035"> </a></td><td>Antimicrobial or antimalarial taken within 72 hours</td></tr><tr><td style="white-space:nowrap">036<a name="cdsi-observation-codes-036"> </a></td><td>Men who have sex with men</td></tr><tr><td style="white-space:nowrap">037<a name="cdsi-observation-codes-037"> </a></td><td>Not in a long-term, mutually monogamous relationship</td></tr><tr><td style="white-space:nowrap">038<a name="cdsi-observation-codes-038"> </a></td><td>Sex partner of Hepatitis B surface antigen-positive persons</td></tr><tr><td style="white-space:nowrap">039<a name="cdsi-observation-codes-039"> </a></td><td>Receives treatment for STD</td></tr><tr><td style="white-space:nowrap">040<a name="cdsi-observation-codes-040"> </a></td><td>Illicit drug use</td></tr><tr><td style="white-space:nowrap">041<a name="cdsi-observation-codes-041"> </a></td><td>Illicit injection drug use</td></tr><tr><td style="white-space:nowrap">042<a name="cdsi-observation-codes-042"> </a></td><td>Smoke cigarettes</td></tr><tr><td style="white-space:nowrap">043<a name="cdsi-observation-codes-043"> </a></td><td>Alcoholism</td></tr><tr><td style="white-space:nowrap">044<a name="cdsi-observation-codes-044"> </a></td><td>Anticipate close personal contact with international adoptee</td></tr><tr><td style="white-space:nowrap">045<a name="cdsi-observation-codes-045"> </a></td><td>Travel to country with a Yellow Fever vaccination entry requirement</td></tr><tr><td style="white-space:nowrap">046<a name="cdsi-observation-codes-046"> </a></td><td>College students living in residence halls</td></tr><tr><td style="white-space:nowrap">047<a name="cdsi-observation-codes-047"> </a></td><td>Resident of area at risk for exposure to the disease</td></tr><tr><td style="white-space:nowrap">048<a name="cdsi-observation-codes-048"> </a></td><td>Travelling Internationally</td></tr><tr><td style="white-space:nowrap">049<a name="cdsi-observation-codes-049"> </a></td><td>Working with Hepatitis A virus in research setting</td></tr><tr><td style="white-space:nowrap">050<a name="cdsi-observation-codes-050"> </a></td><td>Microbiologists routinely exposed to Neisseria meningitidis</td></tr><tr><td style="white-space:nowrap">051<a name="cdsi-observation-codes-051"> </a></td><td>Microbiology laboratorians who work frequently with S. typhi</td></tr><tr><td style="white-space:nowrap">052<a name="cdsi-observation-codes-052"> </a></td><td>Laboratory personnel who might be exposed to YFV</td></tr><tr><td style="white-space:nowrap">053<a name="cdsi-observation-codes-053"> </a></td><td>Rabies researchers</td></tr><tr><td style="white-space:nowrap">054<a name="cdsi-observation-codes-054"> </a></td><td>Laboratory workers who handle specimens that might contain polioviruses</td></tr><tr><td style="white-space:nowrap">055<a name="cdsi-observation-codes-055"> </a></td><td>Health care personnel</td></tr><tr><td style="white-space:nowrap">056<a name="cdsi-observation-codes-056"> </a></td><td>Health-care workers who have close contact with patients who might be excreting wild polioviruses</td></tr><tr><td style="white-space:nowrap">057<a name="cdsi-observation-codes-057"> </a></td><td>Public safety worker exposed to blood or infection body fluids</td></tr><tr><td style="white-space:nowrap">058<a name="cdsi-observation-codes-058"> </a></td><td>Staff of institution for persons with developmental disabilities</td></tr><tr><td style="white-space:nowrap">059<a name="cdsi-observation-codes-059"> </a></td><td>Occupational exposure for Hepatitis A</td></tr><tr><td style="white-space:nowrap">060<a name="cdsi-observation-codes-060"> </a></td><td>Veterinarians and their staff</td></tr><tr><td style="white-space:nowrap">061<a name="cdsi-observation-codes-061"> </a></td><td>Animal handlers</td></tr><tr><td style="white-space:nowrap">062<a name="cdsi-observation-codes-062"> </a></td><td>Persons whose activities bring them into frequent contact with rabies virus or potentially rabid animals</td></tr><tr><td style="white-space:nowrap">063<a name="cdsi-observation-codes-063"> </a></td><td>Post secondary student</td></tr><tr><td style="white-space:nowrap">064<a name="cdsi-observation-codes-064"> </a></td><td>Military recruits</td></tr><tr><td style="white-space:nowrap">065<a name="cdsi-observation-codes-065"> </a></td><td>Client of institution for persons with developmental disabilities</td></tr><tr><td style="white-space:nowrap">066<a name="cdsi-observation-codes-066"> </a></td><td>Chronic renal failure</td></tr><tr><td style="white-space:nowrap">068<a name="cdsi-observation-codes-068"> </a></td><td>In drug abuse treatment and prevention facility</td></tr><tr><td style="white-space:nowrap">069<a name="cdsi-observation-codes-069"> </a></td><td>In correctional facility</td></tr><tr><td style="white-space:nowrap">070<a name="cdsi-observation-codes-070"> </a></td><td>Persons at risk during an outbreak</td></tr><tr><td style="white-space:nowrap">071<a name="cdsi-observation-codes-071"> </a></td><td>Household contact with hepatitis B surface antigen-positive persons</td></tr><tr><td style="white-space:nowrap">072<a name="cdsi-observation-codes-072"> </a></td><td>Intimate exposure to a documented S. typhi carrier</td></tr><tr><td style="white-space:nowrap">073<a name="cdsi-observation-codes-073"> </a></td><td>Household and close contacts of immunocompromised persons</td></tr><tr><td style="white-space:nowrap">074<a name="cdsi-observation-codes-074"> </a></td><td>Negative serological screening for varicella</td></tr><tr><td style="white-space:nowrap">075<a name="cdsi-observation-codes-075"> </a></td><td>Transgender person</td></tr><tr><td style="white-space:nowrap">076<a name="cdsi-observation-codes-076"> </a></td><td>Progressive neurologic disorder</td></tr><tr><td style="white-space:nowrap">077<a name="cdsi-observation-codes-077"> </a></td><td>Received inactivated or unknown measles vaccine between 1963-1967</td></tr><tr><td style="white-space:nowrap">078<a name="cdsi-observation-codes-078"> </a></td><td>Received killed or unknown Mumps vaccine before 1979</td></tr><tr><td style="white-space:nowrap">079<a name="cdsi-observation-codes-079"> </a></td><td>Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine</td></tr><tr><td style="white-space:nowrap">080<a name="cdsi-observation-codes-080"> </a></td><td>Adverse reaction to vaccine component</td></tr><tr><td style="white-space:nowrap">081<a name="cdsi-observation-codes-081"> </a></td><td>Severe allergic reaction after previous dose of Polio</td></tr><tr><td style="white-space:nowrap">082<a name="cdsi-observation-codes-082"> </a></td><td>Severe allergic reaction after previous dose of Japanese Encephalitis</td></tr><tr><td style="white-space:nowrap">083<a name="cdsi-observation-codes-083"> </a></td><td>Severe allergic reaction after previous dose of Rotavirus</td></tr><tr><td style="white-space:nowrap">084<a name="cdsi-observation-codes-084"> </a></td><td>Severe allergic reaction after previous dose of Typhoid</td></tr><tr><td style="white-space:nowrap">085<a name="cdsi-observation-codes-085"> </a></td><td>Severe allergic reaction after previous dose of Influenza</td></tr><tr><td style="white-space:nowrap">086<a name="cdsi-observation-codes-086"> </a></td><td>Severe allergic reaction after previous dose of Pertussis</td></tr><tr><td style="white-space:nowrap">087<a name="cdsi-observation-codes-087"> </a></td><td>Severe allergic reaction after previous dose of Diphtheria</td></tr><tr><td style="white-space:nowrap">088<a name="cdsi-observation-codes-088"> </a></td><td>Severe allergic reaction after previous dose of Tetanus</td></tr><tr><td style="white-space:nowrap">089<a name="cdsi-observation-codes-089"> </a></td><td>Severe allergic reaction after previous dose of Varicella</td></tr><tr><td style="white-space:nowrap">090<a name="cdsi-observation-codes-090"> </a></td><td>Severe allergic reaction after previous dose of HPV</td></tr><tr><td style="white-space:nowrap">091<a name="cdsi-observation-codes-091"> </a></td><td>Severe allergic reaction after previous dose of Measles</td></tr><tr><td style="white-space:nowrap">092<a name="cdsi-observation-codes-092"> </a></td><td>Severe allergic reaction after previous dose of Mumps</td></tr><tr><td style="white-space:nowrap">093<a name="cdsi-observation-codes-093"> </a></td><td>Severe allergic reaction after previous dose of Rubella</td></tr><tr><td style="white-space:nowrap">094<a name="cdsi-observation-codes-094"> </a></td><td>Severe allergic reaction after previous dose of Pneumococcal</td></tr><tr><td style="white-space:nowrap">095<a name="cdsi-observation-codes-095"> </a></td><td>Severe allergic reaction after previous dose of Meningococcal</td></tr><tr><td style="white-space:nowrap">096<a name="cdsi-observation-codes-096"> </a></td><td>Severe allergic reaction after previous dose of Hepatitis A</td></tr><tr><td style="white-space:nowrap">097<a name="cdsi-observation-codes-097"> </a></td><td>Severe allergic reaction after previous dose of Hepatitis B</td></tr><tr><td style="white-space:nowrap">098<a name="cdsi-observation-codes-098"> </a></td><td>Severe allergic reaction after previous dose of Hib</td></tr><tr><td style="white-space:nowrap">099<a name="cdsi-observation-codes-099"> </a></td><td>Severe allergic reaction after previous dose of Yellow Fever</td></tr><tr><td style="white-space:nowrap">100<a name="cdsi-observation-codes-100"> </a></td><td>Severe allergic reaction after previous dose of live zoster</td></tr><tr><td style="white-space:nowrap">101<a name="cdsi-observation-codes-101"> </a></td><td>Allergic reaction to egg protein</td></tr><tr><td style="white-space:nowrap">102<a name="cdsi-observation-codes-102"> </a></td><td>Severe allergic reaction to gelatin</td></tr><tr><td style="white-space:nowrap">103<a name="cdsi-observation-codes-103"> </a></td><td>Severe allergic reaction to arginine</td></tr><tr><td style="white-space:nowrap">104<a name="cdsi-observation-codes-104"> </a></td><td>Allergic reaction to latex</td></tr><tr><td style="white-space:nowrap">105<a name="cdsi-observation-codes-105"> </a></td><td>Severe allergic reaction to chicken protein</td></tr><tr><td style="white-space:nowrap">106<a name="cdsi-observation-codes-106"> </a></td><td>Severe allergic reaction to gentamicin</td></tr><tr><td style="white-space:nowrap">107<a name="cdsi-observation-codes-107"> </a></td><td>Severe allergic reaction to neomycin</td></tr><tr><td style="white-space:nowrap">108<a name="cdsi-observation-codes-108"> </a></td><td>Severe allergic reaction to streptomycin</td></tr><tr><td style="white-space:nowrap">109<a name="cdsi-observation-codes-109"> </a></td><td>Severe allergic reaction to polymyxin B</td></tr><tr><td style="white-space:nowrap">110<a name="cdsi-observation-codes-110"> </a></td><td>Hypersensitivity to yeast</td></tr><tr><td style="white-space:nowrap">111<a name="cdsi-observation-codes-111"> </a></td><td>Hypersensitivity to the preservative 2-phenoxyethanol</td></tr><tr><td style="white-space:nowrap">112<a name="cdsi-observation-codes-112"> </a></td><td>Hypersensitivity to alum</td></tr><tr><td style="white-space:nowrap">113<a name="cdsi-observation-codes-113"> </a></td><td>Severe allergic reaction after previous dose of Rabies</td></tr><tr><td style="white-space:nowrap">114<a name="cdsi-observation-codes-114"> </a></td><td>End stage renal disease</td></tr><tr><td style="white-space:nowrap">115<a name="cdsi-observation-codes-115"> </a></td><td>Severe allergic reaction to protamine sulfate</td></tr><tr><td style="white-space:nowrap">116<a name="cdsi-observation-codes-116"> </a></td><td>Severe allergic reaction after previous dose of Meningococcal B</td></tr><tr><td style="white-space:nowrap">117<a name="cdsi-observation-codes-117"> </a></td><td>Severe allergic reaction to diphtheria toxoid</td></tr><tr><td style="white-space:nowrap">118<a name="cdsi-observation-codes-118"> </a></td><td>Severe allergic reaction to tetanus toxoid</td></tr><tr><td style="white-space:nowrap">119<a name="cdsi-observation-codes-119"> </a></td><td>Severe allergic reaction after previous dose of cholera</td></tr><tr><td style="white-space:nowrap">120<a name="cdsi-observation-codes-120"> </a></td><td>Begin Date of antiviral therapy [ART]</td></tr><tr><td style="white-space:nowrap">121<a name="cdsi-observation-codes-121"> </a></td><td>Homelessness</td></tr><tr><td style="white-space:nowrap">122<a name="cdsi-observation-codes-122"> </a></td><td>Severe allergic reaction after previous dose of COVID-19</td></tr><tr><td style="white-space:nowrap">123<a name="cdsi-observation-codes-123"> </a></td><td>Severe allergic reaction after previous dose of Ebola</td></tr><tr><td style="white-space:nowrap">124<a name="cdsi-observation-codes-124"> </a></td><td>Severe allergic reaction to rice protein </td></tr><tr><td style="white-space:nowrap">125<a name="cdsi-observation-codes-125"> </a></td><td>Tetanus IG administration</td></tr><tr><td style="white-space:nowrap">126<a name="cdsi-observation-codes-126"> </a></td><td>Hep A IG administration</td></tr><tr><td style="white-space:nowrap">127<a name="cdsi-observation-codes-127"> </a></td><td>Hep B IG administration</td></tr><tr><td style="white-space:nowrap">128<a name="cdsi-observation-codes-128"> </a></td><td>Rabies IG administration</td></tr><tr><td style="white-space:nowrap">129<a name="cdsi-observation-codes-129"> </a></td><td>Varicella IG administration</td></tr><tr><td style="white-space:nowrap">130<a name="cdsi-observation-codes-130"> </a></td><td>Measles prophylaxis IG administration - Standard</td></tr><tr><td style="white-space:nowrap">131<a name="cdsi-observation-codes-131"> </a></td><td>Measles prophylaxis IG administration - Immunocompromised Contact</td></tr><tr><td style="white-space:nowrap">132<a name="cdsi-observation-codes-132"> </a></td><td>RBC [adenine-saline added] blood transfusion</td></tr><tr><td style="white-space:nowrap">133<a name="cdsi-observation-codes-133"> </a></td><td>Packed RBC blood transfusion</td></tr><tr><td style="white-space:nowrap">134<a name="cdsi-observation-codes-134"> </a></td><td>Whole blood transfusion</td></tr><tr><td style="white-space:nowrap">135<a name="cdsi-observation-codes-135"> </a></td><td>Plasma/platelet products blood transfusion</td></tr><tr><td style="white-space:nowrap">136<a name="cdsi-observation-codes-136"> </a></td><td>Cytomegalovirus IGIV</td></tr><tr><td style="white-space:nowrap">137<a name="cdsi-observation-codes-137"> </a></td><td>IGIV - Replacement therapy for immune deficiencies</td></tr><tr><td style="white-space:nowrap">138<a name="cdsi-observation-codes-138"> </a></td><td>IGIV - Immune thrombocytopenic purpura treatment</td></tr><tr><td style="white-space:nowrap">139<a name="cdsi-observation-codes-139"> </a></td><td>IGIV - Postexposure varicella prophylaxis</td></tr><tr><td style="white-space:nowrap">140<a name="cdsi-observation-codes-140"> </a></td><td>IGIV - Immune thrombocytopenic purpura treatment</td></tr><tr><td style="white-space:nowrap">141<a name="cdsi-observation-codes-141"> </a></td><td>IGIV - Kawasaki disease</td></tr><tr><td style="white-space:nowrap">142<a name="cdsi-observation-codes-142"> </a></td><td>Travel to or working in countries that have high or intermediate endemicity of Hepatitis A</td></tr><tr><td style="white-space:nowrap">143<a name="cdsi-observation-codes-143"> </a></td><td>Travel to areas or countries where polio is epidemic or endemic</td></tr><tr><td style="white-space:nowrap">144<a name="cdsi-observation-codes-144"> </a></td><td>International travel with possible contact with animals in areas where rabies is enzootic and immediate access to appropriate medical care might be limited</td></tr><tr><td style="white-space:nowrap">145<a name="cdsi-observation-codes-145"> </a></td><td>B-lymphocyte [humoral] - Severe antibody deficiencies</td></tr><tr><td style="white-space:nowrap">146<a name="cdsi-observation-codes-146"> </a></td><td>B-lymphocyte [humoral] - Less severe antibody deficiencies</td></tr><tr><td style="white-space:nowrap">147<a name="cdsi-observation-codes-147"> </a></td><td>T-lymphocyte [cell-mediated and humoral] - Complete defects</td></tr><tr><td style="white-space:nowrap">148<a name="cdsi-observation-codes-148"> </a></td><td>T-lymphocyte [cell-mediated and humoral] - Partial defects</td></tr><tr><td style="white-space:nowrap">149<a name="cdsi-observation-codes-149"> </a></td><td>T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies</td></tr><tr><td style="white-space:nowrap">150<a name="cdsi-observation-codes-150"> </a></td><td>T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha</td></tr><tr><td style="white-space:nowrap">151<a name="cdsi-observation-codes-151"> </a></td><td>Persistent complement, properdin, or factor B deficiency</td></tr><tr><td style="white-space:nowrap">152<a name="cdsi-observation-codes-152"> </a></td><td>Phagocytic function - Chronic granulomatous disease</td></tr><tr><td style="white-space:nowrap">153<a name="cdsi-observation-codes-153"> </a></td><td>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</td></tr><tr><td style="white-space:nowrap">154<a name="cdsi-observation-codes-154"> </a></td><td>HIV/AIDS - severely immunocompromised</td></tr><tr><td style="white-space:nowrap">155<a name="cdsi-observation-codes-155"> </a></td><td>HIV/AIDS - not severely immunocompromised</td></tr><tr><td style="white-space:nowrap">156<a name="cdsi-observation-codes-156"> </a></td><td>Generalized malignant neoplasm</td></tr><tr><td style="white-space:nowrap">157<a name="cdsi-observation-codes-157"> </a></td><td>Transplantation</td></tr><tr><td style="white-space:nowrap">158<a name="cdsi-observation-codes-158"> </a></td><td>Immunosuppressive therapy</td></tr><tr><td style="white-space:nowrap">159<a name="cdsi-observation-codes-159"> </a></td><td>Radiation therapy</td></tr><tr><td style="white-space:nowrap">160<a name="cdsi-observation-codes-160"> </a></td><td>Anatomical or functional asplenia</td></tr><tr><td style="white-space:nowrap">161<a name="cdsi-observation-codes-161"> </a></td><td>Chronic kidney disease</td></tr><tr><td style="white-space:nowrap">162<a name="cdsi-observation-codes-162"> </a></td><td>Travel to areas at risk for Yellow Fever transmission</td></tr><tr><td style="white-space:nowrap">163<a name="cdsi-observation-codes-163"> </a></td><td>Travel to areas in which there is a recognized risk of exposure to S. typhi</td></tr><tr><td style="white-space:nowrap">164<a name="cdsi-observation-codes-164"> </a></td><td>Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic</td></tr><tr><td style="white-space:nowrap">165<a name="cdsi-observation-codes-165"> </a></td><td>Longer-term (e.g., 1 month or more) travel to a JE-endemic area</td></tr><tr><td style="white-space:nowrap">166<a name="cdsi-observation-codes-166"> </a></td><td>Travel to countries with high or intermediate prevalence of chronic HBV infection</td></tr><tr><td style="white-space:nowrap">167<a name="cdsi-observation-codes-167"> </a></td><td>Nephrotic Syndrome</td></tr><tr><td style="white-space:nowrap">168<a name="cdsi-observation-codes-168"> </a></td><td>Chemotherapy</td></tr><tr><td style="white-space:nowrap">169<a name="cdsi-observation-codes-169"> </a></td><td>History of sexual abuse or assault</td></tr><tr><td style="white-space:nowrap">170<a name="cdsi-observation-codes-170"> </a></td><td>Onset of pregnancy</td></tr><tr><td style="white-space:nowrap">171<a name="cdsi-observation-codes-171"> </a></td><td>Date of hematopoietic stem cell transplant</td></tr><tr><td style="white-space:nowrap">172<a name="cdsi-observation-codes-172"> </a></td><td>Severe allergic reaction after previous dose of recombinant zoster</td></tr><tr><td style="white-space:nowrap">173<a name="cdsi-observation-codes-173"> </a></td><td>Moving to JE-endemic country to take up residence</td></tr><tr><td style="white-space:nowrap">174<a name="cdsi-observation-codes-174"> </a></td><td>Frequent travel to JE-endemic areas</td></tr><tr><td style="white-space:nowrap">175<a name="cdsi-observation-codes-175"> </a></td><td>Patient seeks Hepatitis A protection</td></tr><tr><td style="white-space:nowrap">176<a name="cdsi-observation-codes-176"> </a></td><td>Patient seeks Hepatitis B protection</td></tr><tr><td style="white-space:nowrap">177<a name="cdsi-observation-codes-177"> </a></td><td>Patient seeks Meningococcal B protection</td></tr><tr><td style="white-space:nowrap">178<a name="cdsi-observation-codes-178"> </a></td><td>Leukemia</td></tr><tr><td style="white-space:nowrap">179<a name="cdsi-observation-codes-179"> </a></td><td>Lymphoma</td></tr><tr><td style="white-space:nowrap">180<a name="cdsi-observation-codes-180"> </a></td><td>Hodgkin's disease</td></tr><tr><td style="white-space:nowrap">181<a name="cdsi-observation-codes-181"> </a></td><td>Multiple myeloma</td></tr><tr><td style="white-space:nowrap">182<a name="cdsi-observation-codes-182"> </a></td><td>Ebola virus outbreak response</td></tr><tr><td style="white-space:nowrap">183<a name="cdsi-observation-codes-183"> </a></td><td>Health care personnel at federally designated Ebola treatment center in U.S.</td></tr><tr><td style="white-space:nowrap">184<a name="cdsi-observation-codes-184"> </a></td><td>Laboratorians or other staff at biosafety level 4 facilities in U.S.</td></tr><tr><td style="white-space:nowrap">185<a name="cdsi-observation-codes-185"> </a></td><td>Persons in settings that provide services to adults with high proportion of those persons have risk factors for HAV infection</td></tr><tr><td style="white-space:nowrap">186<a name="cdsi-observation-codes-186"> </a></td><td>HIV Infection</td></tr><tr><td style="white-space:nowrap">187<a name="cdsi-observation-codes-187"> </a></td><td>Allergic reaction to polysorbate 80</td></tr><tr><td style="white-space:nowrap">188<a name="cdsi-observation-codes-188"> </a></td><td>Known allergy to Polyethylene glycol [PEG]</td></tr><tr><td style="white-space:nowrap">189<a name="cdsi-observation-codes-189"> </a></td><td>Active treatment for solid tumors</td></tr><tr><td style="white-space:nowrap">190<a name="cdsi-observation-codes-190"> </a></td><td>Active treatment for hematologic malignancies</td></tr><tr><td style="white-space:nowrap">191<a name="cdsi-observation-codes-191"> </a></td><td>Receipt of CAR-T-cell therapy</td></tr><tr><td style="white-space:nowrap">192<a name="cdsi-observation-codes-192"> </a></td><td>Severe allergic reaction after previous dose of any egg-based IIV or LAIV influenza vaccine</td></tr><tr><td style="white-space:nowrap">193<a name="cdsi-observation-codes-193"> </a></td><td>Severe allergic reaction after previous dose of any ccIIV influenza vaccine</td></tr><tr><td style="white-space:nowrap">194<a name="cdsi-observation-codes-194"> </a></td><td>Severe allergic reaction after previous dose of any RIV influenza vaccine</td></tr><tr><td style="white-space:nowrap">195<a name="cdsi-observation-codes-195"> </a></td><td>Occupations at increased risk for COVID-19 exposure and transmission</td></tr><tr><td style="white-space:nowrap">196<a name="cdsi-observation-codes-196"> </a></td><td>Residing in an institutional setting at increased risk for COVID-19 exposure and transmission</td></tr><tr><td style="white-space:nowrap">197<a name="cdsi-observation-codes-197"> </a></td><td>Resident of a long term care facility</td></tr><tr><td style="white-space:nowrap">198<a name="cdsi-observation-codes-198"> </a></td><td>Cancer</td></tr><tr><td style="white-space:nowrap">199<a name="cdsi-observation-codes-199"> </a></td><td>Interstitial lung disease</td></tr><tr><td style="white-space:nowrap">200<a name="cdsi-observation-codes-200"> </a></td><td>Cystic fibrosis</td></tr><tr><td style="white-space:nowrap">201<a name="cdsi-observation-codes-201"> </a></td><td>Pulmonary hypertension</td></tr><tr><td style="white-space:nowrap">202<a name="cdsi-observation-codes-202"> </a></td><td>Dementia</td></tr><tr><td style="white-space:nowrap">203<a name="cdsi-observation-codes-203"> </a></td><td>Down syndrome</td></tr><tr><td style="white-space:nowrap">204<a name="cdsi-observation-codes-204"> </a></td><td>Obesity</td></tr><tr><td style="white-space:nowrap">205<a name="cdsi-observation-codes-205"> </a></td><td>Thalassemia</td></tr><tr><td style="white-space:nowrap">206<a name="cdsi-observation-codes-206"> </a></td><td>Cerebrovascular disease</td></tr><tr><td style="white-space:nowrap">207<a name="cdsi-observation-codes-207"> </a></td><td>Substance use disorder</td></tr><tr><td style="white-space:nowrap">208<a name="cdsi-observation-codes-208"> </a></td><td>Mental Health conditions</td></tr><tr><td style="white-space:nowrap">209<a name="cdsi-observation-codes-209"> </a></td><td>History of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus-vectored COVID-19 vaccines</td></tr><tr><td style="white-space:nowrap">210<a name="cdsi-observation-codes-210"> </a></td><td>Severe allergic reaction after previous dose of Dengue vaccine</td></tr><tr><td style="white-space:nowrap">211<a name="cdsi-observation-codes-211"> </a></td><td>Evidence of previous dengue infection and living in areas where dengue is endemic</td></tr><tr><td style="white-space:nowrap">212<a name="cdsi-observation-codes-212"> </a></td><td>Health care personnel involved in the care and transport of patients with suspected or confirmed Ebola virus disease at Special Pathogen Treatment Centers</td></tr><tr><td style="white-space:nowrap">213<a name="cdsi-observation-codes-213"> </a></td><td>Laboratorians and support staff members at Laboratory Response Network (LRN) facilities that handle specimens that might contain replication-competent Ebola virus in the United States</td></tr><tr><td style="white-space:nowrap">214<a name="cdsi-observation-codes-214"> </a></td><td>Chronic obstructive pulmonary disease</td></tr><tr><td style="white-space:nowrap">215<a name="cdsi-observation-codes-215"> </a></td><td>Emphysema</td></tr><tr><td style="white-space:nowrap">216<a name="cdsi-observation-codes-216"> </a></td><td>Iatrogenic Immunosuppression</td></tr><tr><td style="white-space:nowrap">217<a name="cdsi-observation-codes-217"> </a></td><td>Persons working in rabies vaccine production facilities</td></tr><tr><td style="white-space:nowrap">218<a name="cdsi-observation-codes-218"> </a></td><td>Persons performing testing for rabies in diagnostic laboratories</td></tr><tr><td style="white-space:nowrap">219<a name="cdsi-observation-codes-219"> </a></td><td>Persons who frequently handle bats</td></tr><tr><td style="white-space:nowrap">220<a name="cdsi-observation-codes-220"> </a></td><td>Persons who frequently have contact with bats</td></tr><tr><td style="white-space:nowrap">221<a name="cdsi-observation-codes-221"> </a></td><td>Persons who frequently enter high-density bat environments</td></tr><tr><td style="white-space:nowrap">222<a name="cdsi-observation-codes-222"> </a></td><td>Persons who frequently perform animal necropsies</td></tr><tr><td style="white-space:nowrap">223<a name="cdsi-observation-codes-223"> </a></td><td>Severe allergic reaction after previous dose of orthopoxvirus vaccine</td></tr><tr><td style="white-space:nowrap">224<a name="cdsi-observation-codes-224"> </a></td><td>History or presence of atopic dermatitis</td></tr><tr><td style="white-space:nowrap">225<a name="cdsi-observation-codes-225"> </a></td><td>Household contact with history or presence of atopic dermatitis</td></tr><tr><td style="white-space:nowrap">226<a name="cdsi-observation-codes-226"> </a></td><td>Active exfoliative skin conditions</td></tr><tr><td style="white-space:nowrap">227<a name="cdsi-observation-codes-227"> </a></td><td>Household contact with active exfoliative skin conditions</td></tr><tr><td style="white-space:nowrap">228<a name="cdsi-observation-codes-228"> </a></td><td>Household contact is pregnant</td></tr><tr><td style="white-space:nowrap">229<a name="cdsi-observation-codes-229"> </a></td><td>Age is less than 1 year</td></tr><tr><td style="white-space:nowrap">230<a name="cdsi-observation-codes-230"> </a></td><td>Household contact who is less than 1 year of age</td></tr><tr><td style="white-space:nowrap">231<a name="cdsi-observation-codes-231"> </a></td><td>3 or more known major cardiac risk factors</td></tr><tr><td style="white-space:nowrap">232<a name="cdsi-observation-codes-232"> </a></td><td>Research laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)</td></tr><tr><td style="white-space:nowrap">233<a name="cdsi-observation-codes-233"> </a></td><td>Clinical laboratory personnel performing diagnostic testing for more virulent orthopoxviruses (e.g., Variola virus or mpox virus)</td></tr><tr><td style="white-space:nowrap">234<a name="cdsi-observation-codes-234"> </a></td><td>Designated response team members working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)</td></tr><tr><td style="white-space:nowrap">235<a name="cdsi-observation-codes-235"> </a></td><td>Healthcare personnel who care for patients infected with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)</td></tr><tr><td style="white-space:nowrap">236<a name="cdsi-observation-codes-236"> </a></td><td>Research laboratory personnel working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)</td></tr><tr><td style="white-space:nowrap">237<a name="cdsi-observation-codes-237"> </a></td><td>Clinical laboratory personnel performing diagnostic testing for less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)</td></tr><tr><td style="white-space:nowrap">238<a name="cdsi-observation-codes-238"> </a></td><td>Designated response team members working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)</td></tr><tr><td style="white-space:nowrap">239<a name="cdsi-observation-codes-239"> </a></td><td>Healthcare personnel who administer ACAM2000</td></tr><tr><td style="white-space:nowrap">240<a name="cdsi-observation-codes-240"> </a></td><td>Healthcare personnel who care for patients infected with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)</td></tr><tr><td style="white-space:nowrap">241<a name="cdsi-observation-codes-241"> </a></td><td>Known exposure to mpox</td></tr><tr><td style="white-space:nowrap">242<a name="cdsi-observation-codes-242"> </a></td><td>Presumed exposure to mpox</td></tr><tr><td style="white-space:nowrap">243<a name="cdsi-observation-codes-243"> </a></td><td>Lack of laboratory confirmation of a previous Dengue infection</td></tr><tr><td style="white-space:nowrap">244<a name="cdsi-observation-codes-244"> </a></td><td>Severe allergic reaction after previous dose of RSV vaccine</td></tr><tr><td style="white-space:nowrap">245<a name="cdsi-observation-codes-245"> </a></td><td>American Indian or Alaskan Native</td></tr><tr><td style="white-space:nowrap">246<a name="cdsi-observation-codes-246"> </a></td><td>Severe immunocompromise</td></tr><tr><td style="white-space:nowrap">247<a name="cdsi-observation-codes-247"> </a></td><td>Gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following:  1) A new diagnosis of ≥ 1 sexually transmitted disease 2)  More than one sex partner 3)  Sex at a commercial sex venue 4)   Sex in association with a large public event in a geographic area where mpox transmission is occurring</td></tr><tr><td style="white-space:nowrap">248<a name="cdsi-observation-codes-248"> </a></td><td>Sexual partners of gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following:  1) A new diagnosis of ≥ 1 sexually transmitted disease 2)  More than one sex partner 3)  Sex at a commercial sex venue 4)   Sex in association with a large public event in a geographic area where mpox transmission is occurring</td></tr><tr><td style="white-space:nowrap">249<a name="cdsi-observation-codes-249"> </a></td><td>Moving or traveling to an area where TBE is endemic and will have extensive exposure to ticks because of their planned outdoor activities and itinerary</td></tr><tr><td style="white-space:nowrap">250<a name="cdsi-observation-codes-250"> </a></td><td>Moving or traveling to an area where TBE is endemic who might engage in outdoor activities in areas where ticks are likely to be found</td></tr><tr><td style="white-space:nowrap">251<a name="cdsi-observation-codes-251"> </a></td><td>Laboratory workers with a potential for exposure to TBE virus</td></tr><tr><td style="white-space:nowrap">252<a name="cdsi-observation-codes-252"> </a></td><td>Severe allergic reaction after previous dose of Tick-borne Encephalitis vaccine</td></tr></table></div>
  </text>
  <url value="http://fhirfli.dev/fhir/ig/cicada/CodeSystem/cdsi-observation-codes"/>
  <version value="0.1.0"/>
  <name value="CdsiObservationCodes"/>
  <title value="CDSI Observation Codes"/>
  <status value="draft"/>
  <date value="2026-02-11T14:37:07-05:00"/>
  <publisher value="FHIR-FLI"/>
  <contact>
    <name value="FHIR-FLI"/>
    <telecom>
      <system value="url"/>
      <value value="http://fhirfli.dev"/>
    </telecom>
  </contact>
  <description value="Observations and Conditions that are important to indications or contraindications in vaccine forecasting"/>
  <content value="complete"/>
  <count value="251"/>
  <concept>
    <code value="001"/>
    <display value="001"/>
    <definition value="Patient seeks protection"/>
  </concept>
  <concept>
    <code value="002"/>
    <display value="002"/>
    <definition value="Undergoing elective splenectomy"/>
  </concept>
  <concept>
    <code value="003"/>
    <display value="003"/>
    <definition value="Immunocompromised"/>
  </concept>
  <concept>
    <code value="004"/>
    <display value="004"/>
    <definition value="Recipient of a hematopoietic stem cell transplant"/>
  </concept>
  <concept>
    <code value="005"/>
    <display value="005"/>
    <definition value="Hepatitis C virus infection"/>
  </concept>
  <concept>
    <code value="006"/>
    <display value="006"/>
    <definition value="Receives clotting factor concentrates"/>
  </concept>
  <concept>
    <code value="007"/>
    <display value="007"/>
    <definition value="Pregnant"/>
  </concept>
  <concept>
    <code value="008"/>
    <display value="008"/>
    <definition value="Travel to an area of active cholera transmission"/>
  </concept>
  <concept>
    <code value="009"/>
    <display value="009"/>
    <definition value="Breastfeeding"/>
  </concept>
  <concept>
    <code value="010"/>
    <display value="010"/>
    <definition value="Cerebrospinal fluid leaks"/>
  </concept>
  <concept>
    <code value="011"/>
    <display value="011"/>
    <definition value="Cochlear implants"/>
  </concept>
  <concept>
    <code value="012"/>
    <display value="012"/>
    <definition value="Family history of altered immunocompetence"/>
  </concept>
  <concept>
    <code value="013"/>
    <display value="013"/>
    <definition value="Severe Combined Immunodeficiency [SCID]"/>
  </concept>
  <concept>
    <code value="014"/>
    <display value="014"/>
    <definition value="Diabetes"/>
  </concept>
  <concept>
    <code value="015"/>
    <display value="015"/>
    <definition value="Chronic liver disease"/>
  </concept>
  <concept>
    <code value="016"/>
    <display value="016"/>
    <definition value="Chronic heart disease"/>
  </concept>
  <concept>
    <code value="017"/>
    <display value="017"/>
    <definition value="Chronic lung disease"/>
  </concept>
  <concept>
    <code value="018"/>
    <display value="018"/>
    <definition value="Laboratory Evidence of Immunity or confirmation of Hepatitis A disease"/>
  </concept>
  <concept>
    <code value="019"/>
    <display value="019"/>
    <definition value="Laboratory Evidence of Immunity or confirmation of Hepatitis B disease"/>
  </concept>
  <concept>
    <code value="020"/>
    <display value="020"/>
    <definition value="Laboratory Evidence of Immunity for Measles"/>
  </concept>
  <concept>
    <code value="021"/>
    <display value="021"/>
    <definition value="Laboratory Evidence of Immunity for Mumps"/>
  </concept>
  <concept>
    <code value="022"/>
    <display value="022"/>
    <definition value="Laboratory Evidence of Immunity for Rubella"/>
  </concept>
  <concept>
    <code value="023"/>
    <display value="023"/>
    <definition value="Laboratory Evidence of Immunity or confirmation of Varicella disease"/>
  </concept>
  <concept>
    <code value="024"/>
    <display value="024"/>
    <definition value="Healthcare provider verified history of or diagnosis of Varicella"/>
  </concept>
  <concept>
    <code value="025"/>
    <display value="025"/>
    <definition value="Healthcare provider verified history or diagnosis of Herpes Zoster"/>
  </concept>
  <concept>
    <code value="026"/>
    <display value="026"/>
    <definition value="Persons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]"/>
  </concept>
  <concept>
    <code value="027"/>
    <display value="027"/>
    <definition value="Asthma"/>
  </concept>
  <concept>
    <code value="028"/>
    <display value="028"/>
    <definition value="Intussusception"/>
  </concept>
  <concept>
    <code value="029"/>
    <display value="029"/>
    <definition value="Acute gastroenteritis"/>
  </concept>
  <concept>
    <code value="030"/>
    <display value="030"/>
    <definition value="Acute febrile illness"/>
  </concept>
  <concept>
    <code value="031"/>
    <display value="031"/>
    <definition value="Tuberculosis"/>
  </concept>
  <concept>
    <code value="032"/>
    <display value="032"/>
    <definition value="Dialysis patient"/>
  </concept>
  <concept>
    <code value="033"/>
    <display value="033"/>
    <definition value="Taken influenza antiviral medications within the previous 48 hours"/>
  </concept>
  <concept>
    <code value="034"/>
    <display value="034"/>
    <definition value="Receiving long-term aspirin therapy"/>
  </concept>
  <concept>
    <code value="035"/>
    <display value="035"/>
    <definition value="Antimicrobial or antimalarial taken within 72 hours"/>
  </concept>
  <concept>
    <code value="036"/>
    <display value="036"/>
    <definition value="Men who have sex with men"/>
  </concept>
  <concept>
    <code value="037"/>
    <display value="037"/>
    <definition value="Not in a long-term, mutually monogamous relationship"/>
  </concept>
  <concept>
    <code value="038"/>
    <display value="038"/>
    <definition value="Sex partner of Hepatitis B surface antigen-positive persons"/>
  </concept>
  <concept>
    <code value="039"/>
    <display value="039"/>
    <definition value="Receives treatment for STD"/>
  </concept>
  <concept>
    <code value="040"/>
    <display value="040"/>
    <definition value="Illicit drug use"/>
  </concept>
  <concept>
    <code value="041"/>
    <display value="041"/>
    <definition value="Illicit injection drug use"/>
  </concept>
  <concept>
    <code value="042"/>
    <display value="042"/>
    <definition value="Smoke cigarettes"/>
  </concept>
  <concept>
    <code value="043"/>
    <display value="043"/>
    <definition value="Alcoholism"/>
  </concept>
  <concept>
    <code value="044"/>
    <display value="044"/>
    <definition value="Anticipate close personal contact with international adoptee"/>
  </concept>
  <concept>
    <code value="045"/>
    <display value="045"/>
    <definition value="Travel to country with a Yellow Fever vaccination entry requirement"/>
  </concept>
  <concept>
    <code value="046"/>
    <display value="046"/>
    <definition value="College students living in residence halls"/>
  </concept>
  <concept>
    <code value="047"/>
    <display value="047"/>
    <definition value="Resident of area at risk for exposure to the disease"/>
  </concept>
  <concept>
    <code value="048"/>
    <display value="048"/>
    <definition value="Travelling Internationally"/>
  </concept>
  <concept>
    <code value="049"/>
    <display value="049"/>
    <definition value="Working with Hepatitis A virus in research setting"/>
  </concept>
  <concept>
    <code value="050"/>
    <display value="050"/>
    <definition value="Microbiologists routinely exposed to Neisseria meningitidis"/>
  </concept>
  <concept>
    <code value="051"/>
    <display value="051"/>
    <definition value="Microbiology laboratorians who work frequently with S. typhi"/>
  </concept>
  <concept>
    <code value="052"/>
    <display value="052"/>
    <definition value="Laboratory personnel who might be exposed to YFV"/>
  </concept>
  <concept>
    <code value="053"/>
    <display value="053"/>
    <definition value="Rabies researchers"/>
  </concept>
  <concept>
    <code value="054"/>
    <display value="054"/>
    <definition value="Laboratory workers who handle specimens that might contain polioviruses"/>
  </concept>
  <concept>
    <code value="055"/>
    <display value="055"/>
    <definition value="Health care personnel"/>
  </concept>
  <concept>
    <code value="056"/>
    <display value="056"/>
    <definition value="Health-care workers who have close contact with patients who might be excreting wild polioviruses"/>
  </concept>
  <concept>
    <code value="057"/>
    <display value="057"/>
    <definition value="Public safety worker exposed to blood or infection body fluids"/>
  </concept>
  <concept>
    <code value="058"/>
    <display value="058"/>
    <definition value="Staff of institution for persons with developmental disabilities"/>
  </concept>
  <concept>
    <code value="059"/>
    <display value="059"/>
    <definition value="Occupational exposure for Hepatitis A"/>
  </concept>
  <concept>
    <code value="060"/>
    <display value="060"/>
    <definition value="Veterinarians and their staff"/>
  </concept>
  <concept>
    <code value="061"/>
    <display value="061"/>
    <definition value="Animal handlers"/>
  </concept>
  <concept>
    <code value="062"/>
    <display value="062"/>
    <definition value="Persons whose activities bring them into frequent contact with rabies virus or potentially rabid animals"/>
  </concept>
  <concept>
    <code value="063"/>
    <display value="063"/>
    <definition value="Post secondary student"/>
  </concept>
  <concept>
    <code value="064"/>
    <display value="064"/>
    <definition value="Military recruits"/>
  </concept>
  <concept>
    <code value="065"/>
    <display value="065"/>
    <definition value="Client of institution for persons with developmental disabilities"/>
  </concept>
  <concept>
    <code value="066"/>
    <display value="066"/>
    <definition value="Chronic renal failure"/>
  </concept>
  <concept>
    <code value="068"/>
    <display value="068"/>
    <definition value="In drug abuse treatment and prevention facility"/>
  </concept>
  <concept>
    <code value="069"/>
    <display value="069"/>
    <definition value="In correctional facility"/>
  </concept>
  <concept>
    <code value="070"/>
    <display value="070"/>
    <definition value="Persons at risk during an outbreak"/>
  </concept>
  <concept>
    <code value="071"/>
    <display value="071"/>
    <definition value="Household contact with hepatitis B surface antigen-positive persons"/>
  </concept>
  <concept>
    <code value="072"/>
    <display value="072"/>
    <definition value="Intimate exposure to a documented S. typhi carrier"/>
  </concept>
  <concept>
    <code value="073"/>
    <display value="073"/>
    <definition value="Household and close contacts of immunocompromised persons"/>
  </concept>
  <concept>
    <code value="074"/>
    <display value="074"/>
    <definition value="Negative serological screening for varicella"/>
  </concept>
  <concept>
    <code value="075"/>
    <display value="075"/>
    <definition value="Transgender person"/>
  </concept>
  <concept>
    <code value="076"/>
    <display value="076"/>
    <definition value="Progressive neurologic disorder"/>
  </concept>
  <concept>
    <code value="077"/>
    <display value="077"/>
    <definition value="Received inactivated or unknown measles vaccine between 1963-1967"/>
  </concept>
  <concept>
    <code value="078"/>
    <display value="078"/>
    <definition value="Received killed or unknown Mumps vaccine before 1979"/>
  </concept>
  <concept>
    <code value="079"/>
    <display value="079"/>
    <definition value="Encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine"/>
  </concept>
  <concept>
    <code value="080"/>
    <display value="080"/>
    <definition value="Adverse reaction to vaccine component"/>
  </concept>
  <concept>
    <code value="081"/>
    <display value="081"/>
    <definition value="Severe allergic reaction after previous dose of Polio"/>
  </concept>
  <concept>
    <code value="082"/>
    <display value="082"/>
    <definition value="Severe allergic reaction after previous dose of Japanese Encephalitis"/>
  </concept>
  <concept>
    <code value="083"/>
    <display value="083"/>
    <definition value="Severe allergic reaction after previous dose of Rotavirus"/>
  </concept>
  <concept>
    <code value="084"/>
    <display value="084"/>
    <definition value="Severe allergic reaction after previous dose of Typhoid"/>
  </concept>
  <concept>
    <code value="085"/>
    <display value="085"/>
    <definition value="Severe allergic reaction after previous dose of Influenza"/>
  </concept>
  <concept>
    <code value="086"/>
    <display value="086"/>
    <definition value="Severe allergic reaction after previous dose of Pertussis"/>
  </concept>
  <concept>
    <code value="087"/>
    <display value="087"/>
    <definition value="Severe allergic reaction after previous dose of Diphtheria"/>
  </concept>
  <concept>
    <code value="088"/>
    <display value="088"/>
    <definition value="Severe allergic reaction after previous dose of Tetanus"/>
  </concept>
  <concept>
    <code value="089"/>
    <display value="089"/>
    <definition value="Severe allergic reaction after previous dose of Varicella"/>
  </concept>
  <concept>
    <code value="090"/>
    <display value="090"/>
    <definition value="Severe allergic reaction after previous dose of HPV"/>
  </concept>
  <concept>
    <code value="091"/>
    <display value="091"/>
    <definition value="Severe allergic reaction after previous dose of Measles"/>
  </concept>
  <concept>
    <code value="092"/>
    <display value="092"/>
    <definition value="Severe allergic reaction after previous dose of Mumps"/>
  </concept>
  <concept>
    <code value="093"/>
    <display value="093"/>
    <definition value="Severe allergic reaction after previous dose of Rubella"/>
  </concept>
  <concept>
    <code value="094"/>
    <display value="094"/>
    <definition value="Severe allergic reaction after previous dose of Pneumococcal"/>
  </concept>
  <concept>
    <code value="095"/>
    <display value="095"/>
    <definition value="Severe allergic reaction after previous dose of Meningococcal"/>
  </concept>
  <concept>
    <code value="096"/>
    <display value="096"/>
    <definition value="Severe allergic reaction after previous dose of Hepatitis A"/>
  </concept>
  <concept>
    <code value="097"/>
    <display value="097"/>
    <definition value="Severe allergic reaction after previous dose of Hepatitis B"/>
  </concept>
  <concept>
    <code value="098"/>
    <display value="098"/>
    <definition value="Severe allergic reaction after previous dose of Hib"/>
  </concept>
  <concept>
    <code value="099"/>
    <display value="099"/>
    <definition value="Severe allergic reaction after previous dose of Yellow Fever"/>
  </concept>
  <concept>
    <code value="100"/>
    <display value="100"/>
    <definition value="Severe allergic reaction after previous dose of live zoster"/>
  </concept>
  <concept>
    <code value="101"/>
    <display value="101"/>
    <definition value="Allergic reaction to egg protein"/>
  </concept>
  <concept>
    <code value="102"/>
    <display value="102"/>
    <definition value="Severe allergic reaction to gelatin"/>
  </concept>
  <concept>
    <code value="103"/>
    <display value="103"/>
    <definition value="Severe allergic reaction to arginine"/>
  </concept>
  <concept>
    <code value="104"/>
    <display value="104"/>
    <definition value="Allergic reaction to latex"/>
  </concept>
  <concept>
    <code value="105"/>
    <display value="105"/>
    <definition value="Severe allergic reaction to chicken protein"/>
  </concept>
  <concept>
    <code value="106"/>
    <display value="106"/>
    <definition value="Severe allergic reaction to gentamicin"/>
  </concept>
  <concept>
    <code value="107"/>
    <display value="107"/>
    <definition value="Severe allergic reaction to neomycin"/>
  </concept>
  <concept>
    <code value="108"/>
    <display value="108"/>
    <definition value="Severe allergic reaction to streptomycin"/>
  </concept>
  <concept>
    <code value="109"/>
    <display value="109"/>
    <definition value="Severe allergic reaction to polymyxin B"/>
  </concept>
  <concept>
    <code value="110"/>
    <display value="110"/>
    <definition value="Hypersensitivity to yeast"/>
  </concept>
  <concept>
    <code value="111"/>
    <display value="111"/>
    <definition value="Hypersensitivity to the preservative 2-phenoxyethanol"/>
  </concept>
  <concept>
    <code value="112"/>
    <display value="112"/>
    <definition value="Hypersensitivity to alum"/>
  </concept>
  <concept>
    <code value="113"/>
    <display value="113"/>
    <definition value="Severe allergic reaction after previous dose of Rabies"/>
  </concept>
  <concept>
    <code value="114"/>
    <display value="114"/>
    <definition value="End stage renal disease"/>
  </concept>
  <concept>
    <code value="115"/>
    <display value="115"/>
    <definition value="Severe allergic reaction to protamine sulfate"/>
  </concept>
  <concept>
    <code value="116"/>
    <display value="116"/>
    <definition value="Severe allergic reaction after previous dose of Meningococcal B"/>
  </concept>
  <concept>
    <code value="117"/>
    <display value="117"/>
    <definition value="Severe allergic reaction to diphtheria toxoid"/>
  </concept>
  <concept>
    <code value="118"/>
    <display value="118"/>
    <definition value="Severe allergic reaction to tetanus toxoid"/>
  </concept>
  <concept>
    <code value="119"/>
    <display value="119"/>
    <definition value="Severe allergic reaction after previous dose of cholera"/>
  </concept>
  <concept>
    <code value="120"/>
    <display value="120"/>
    <definition value="Begin Date of antiviral therapy [ART]"/>
  </concept>
  <concept>
    <code value="121"/>
    <display value="121"/>
    <definition value="Homelessness"/>
  </concept>
  <concept>
    <code value="122"/>
    <display value="122"/>
    <definition value="Severe allergic reaction after previous dose of COVID-19"/>
  </concept>
  <concept>
    <code value="123"/>
    <display value="123"/>
    <definition value="Severe allergic reaction after previous dose of Ebola"/>
  </concept>
  <concept>
    <code value="124"/>
    <display value="124"/>
    <definition value="Severe allergic reaction to rice protein "/>
  </concept>
  <concept>
    <code value="125"/>
    <display value="125"/>
    <definition value="Tetanus IG administration"/>
  </concept>
  <concept>
    <code value="126"/>
    <display value="126"/>
    <definition value="Hep A IG administration"/>
  </concept>
  <concept>
    <code value="127"/>
    <display value="127"/>
    <definition value="Hep B IG administration"/>
  </concept>
  <concept>
    <code value="128"/>
    <display value="128"/>
    <definition value="Rabies IG administration"/>
  </concept>
  <concept>
    <code value="129"/>
    <display value="129"/>
    <definition value="Varicella IG administration"/>
  </concept>
  <concept>
    <code value="130"/>
    <display value="130"/>
    <definition value="Measles prophylaxis IG administration - Standard"/>
  </concept>
  <concept>
    <code value="131"/>
    <display value="131"/>
    <definition value="Measles prophylaxis IG administration - Immunocompromised Contact"/>
  </concept>
  <concept>
    <code value="132"/>
    <display value="132"/>
    <definition value="RBC [adenine-saline added] blood transfusion"/>
  </concept>
  <concept>
    <code value="133"/>
    <display value="133"/>
    <definition value="Packed RBC blood transfusion"/>
  </concept>
  <concept>
    <code value="134"/>
    <display value="134"/>
    <definition value="Whole blood transfusion"/>
  </concept>
  <concept>
    <code value="135"/>
    <display value="135"/>
    <definition value="Plasma/platelet products blood transfusion"/>
  </concept>
  <concept>
    <code value="136"/>
    <display value="136"/>
    <definition value="Cytomegalovirus IGIV"/>
  </concept>
  <concept>
    <code value="137"/>
    <display value="137"/>
    <definition value="IGIV - Replacement therapy for immune deficiencies"/>
  </concept>
  <concept>
    <code value="138"/>
    <display value="138"/>
    <definition value="IGIV - Immune thrombocytopenic purpura treatment"/>
  </concept>
  <concept>
    <code value="139"/>
    <display value="139"/>
    <definition value="IGIV - Postexposure varicella prophylaxis"/>
  </concept>
  <concept>
    <code value="140"/>
    <display value="140"/>
    <definition value="IGIV - Immune thrombocytopenic purpura treatment"/>
  </concept>
  <concept>
    <code value="141"/>
    <display value="141"/>
    <definition value="IGIV - Kawasaki disease"/>
  </concept>
  <concept>
    <code value="142"/>
    <display value="142"/>
    <definition value="Travel to or working in countries that have high or intermediate endemicity of Hepatitis A"/>
  </concept>
  <concept>
    <code value="143"/>
    <display value="143"/>
    <definition value="Travel to areas or countries where polio is epidemic or endemic"/>
  </concept>
  <concept>
    <code value="144"/>
    <display value="144"/>
    <definition value="International travel with possible contact with animals in areas where rabies is enzootic and immediate access to appropriate medical care might be limited"/>
  </concept>
  <concept>
    <code value="145"/>
    <display value="145"/>
    <definition value="B-lymphocyte [humoral] - Severe antibody deficiencies"/>
  </concept>
  <concept>
    <code value="146"/>
    <display value="146"/>
    <definition value="B-lymphocyte [humoral] - Less severe antibody deficiencies"/>
  </concept>
  <concept>
    <code value="147"/>
    <display value="147"/>
    <definition value="T-lymphocyte [cell-mediated and humoral] - Complete defects"/>
  </concept>
  <concept>
    <code value="148"/>
    <display value="148"/>
    <definition value="T-lymphocyte [cell-mediated and humoral] - Partial defects"/>
  </concept>
  <concept>
    <code value="149"/>
    <display value="149"/>
    <definition value="T-lymphocyte [cell-mediated and humoral] - interferon-gamma/Interleukin 12 axis deficiencies"/>
  </concept>
  <concept>
    <code value="150"/>
    <display value="150"/>
    <definition value="T-lymphocyte [cell-mediated and humoral] - interferon-gamma or interferon-alpha"/>
  </concept>
  <concept>
    <code value="151"/>
    <display value="151"/>
    <definition value="Persistent complement, properdin, or factor B deficiency"/>
  </concept>
  <concept>
    <code value="152"/>
    <display value="152"/>
    <definition value="Phagocytic function - Chronic granulomatous disease"/>
  </concept>
  <concept>
    <code value="153"/>
    <display value="153"/>
    <definition value="Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency"/>
  </concept>
  <concept>
    <code value="154"/>
    <display value="154"/>
    <definition value="HIV/AIDS - severely immunocompromised"/>
  </concept>
  <concept>
    <code value="155"/>
    <display value="155"/>
    <definition value="HIV/AIDS - not severely immunocompromised"/>
  </concept>
  <concept>
    <code value="156"/>
    <display value="156"/>
    <definition value="Generalized malignant neoplasm"/>
  </concept>
  <concept>
    <code value="157"/>
    <display value="157"/>
    <definition value="Transplantation"/>
  </concept>
  <concept>
    <code value="158"/>
    <display value="158"/>
    <definition value="Immunosuppressive therapy"/>
  </concept>
  <concept>
    <code value="159"/>
    <display value="159"/>
    <definition value="Radiation therapy"/>
  </concept>
  <concept>
    <code value="160"/>
    <display value="160"/>
    <definition value="Anatomical or functional asplenia"/>
  </concept>
  <concept>
    <code value="161"/>
    <display value="161"/>
    <definition value="Chronic kidney disease"/>
  </concept>
  <concept>
    <code value="162"/>
    <display value="162"/>
    <definition value="Travel to areas at risk for Yellow Fever transmission"/>
  </concept>
  <concept>
    <code value="163"/>
    <display value="163"/>
    <definition value="Travel to areas in which there is a recognized risk of exposure to S. typhi"/>
  </concept>
  <concept>
    <code value="164"/>
    <display value="164"/>
    <definition value="Travel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic"/>
  </concept>
  <concept>
    <code value="165"/>
    <display value="165"/>
    <definition value="Longer-term (e.g., 1 month or more) travel to a JE-endemic area"/>
  </concept>
  <concept>
    <code value="166"/>
    <display value="166"/>
    <definition value="Travel to countries with high or intermediate prevalence of chronic HBV infection"/>
  </concept>
  <concept>
    <code value="167"/>
    <display value="167"/>
    <definition value="Nephrotic Syndrome"/>
  </concept>
  <concept>
    <code value="168"/>
    <display value="168"/>
    <definition value="Chemotherapy"/>
  </concept>
  <concept>
    <code value="169"/>
    <display value="169"/>
    <definition value="History of sexual abuse or assault"/>
  </concept>
  <concept>
    <code value="170"/>
    <display value="170"/>
    <definition value="Onset of pregnancy"/>
  </concept>
  <concept>
    <code value="171"/>
    <display value="171"/>
    <definition value="Date of hematopoietic stem cell transplant"/>
  </concept>
  <concept>
    <code value="172"/>
    <display value="172"/>
    <definition value="Severe allergic reaction after previous dose of recombinant zoster"/>
  </concept>
  <concept>
    <code value="173"/>
    <display value="173"/>
    <definition value="Moving to JE-endemic country to take up residence"/>
  </concept>
  <concept>
    <code value="174"/>
    <display value="174"/>
    <definition value="Frequent travel to JE-endemic areas"/>
  </concept>
  <concept>
    <code value="175"/>
    <display value="175"/>
    <definition value="Patient seeks Hepatitis A protection"/>
  </concept>
  <concept>
    <code value="176"/>
    <display value="176"/>
    <definition value="Patient seeks Hepatitis B protection"/>
  </concept>
  <concept>
    <code value="177"/>
    <display value="177"/>
    <definition value="Patient seeks Meningococcal B protection"/>
  </concept>
  <concept>
    <code value="178"/>
    <display value="178"/>
    <definition value="Leukemia"/>
  </concept>
  <concept>
    <code value="179"/>
    <display value="179"/>
    <definition value="Lymphoma"/>
  </concept>
  <concept>
    <code value="180"/>
    <display value="180"/>
    <definition value="Hodgkin's disease"/>
  </concept>
  <concept>
    <code value="181"/>
    <display value="181"/>
    <definition value="Multiple myeloma"/>
  </concept>
  <concept>
    <code value="182"/>
    <display value="182"/>
    <definition value="Ebola virus outbreak response"/>
  </concept>
  <concept>
    <code value="183"/>
    <display value="183"/>
    <definition value="Health care personnel at federally designated Ebola treatment center in U.S."/>
  </concept>
  <concept>
    <code value="184"/>
    <display value="184"/>
    <definition value="Laboratorians or other staff at biosafety level 4 facilities in U.S."/>
  </concept>
  <concept>
    <code value="185"/>
    <display value="185"/>
    <definition value="Persons in settings that provide services to adults with high proportion of those persons have risk factors for HAV infection"/>
  </concept>
  <concept>
    <code value="186"/>
    <display value="186"/>
    <definition value="HIV Infection"/>
  </concept>
  <concept>
    <code value="187"/>
    <display value="187"/>
    <definition value="Allergic reaction to polysorbate 80"/>
  </concept>
  <concept>
    <code value="188"/>
    <display value="188"/>
    <definition value="Known allergy to Polyethylene glycol [PEG]"/>
  </concept>
  <concept>
    <code value="189"/>
    <display value="189"/>
    <definition value="Active treatment for solid tumors"/>
  </concept>
  <concept>
    <code value="190"/>
    <display value="190"/>
    <definition value="Active treatment for hematologic malignancies"/>
  </concept>
  <concept>
    <code value="191"/>
    <display value="191"/>
    <definition value="Receipt of CAR-T-cell therapy"/>
  </concept>
  <concept>
    <code value="192"/>
    <display value="192"/>
    <definition value="Severe allergic reaction after previous dose of any egg-based IIV or LAIV influenza vaccine"/>
  </concept>
  <concept>
    <code value="193"/>
    <display value="193"/>
    <definition value="Severe allergic reaction after previous dose of any ccIIV influenza vaccine"/>
  </concept>
  <concept>
    <code value="194"/>
    <display value="194"/>
    <definition value="Severe allergic reaction after previous dose of any RIV influenza vaccine"/>
  </concept>
  <concept>
    <code value="195"/>
    <display value="195"/>
    <definition value="Occupations at increased risk for COVID-19 exposure and transmission"/>
  </concept>
  <concept>
    <code value="196"/>
    <display value="196"/>
    <definition value="Residing in an institutional setting at increased risk for COVID-19 exposure and transmission"/>
  </concept>
  <concept>
    <code value="197"/>
    <display value="197"/>
    <definition value="Resident of a long term care facility"/>
  </concept>
  <concept>
    <code value="198"/>
    <display value="198"/>
    <definition value="Cancer"/>
  </concept>
  <concept>
    <code value="199"/>
    <display value="199"/>
    <definition value="Interstitial lung disease"/>
  </concept>
  <concept>
    <code value="200"/>
    <display value="200"/>
    <definition value="Cystic fibrosis"/>
  </concept>
  <concept>
    <code value="201"/>
    <display value="201"/>
    <definition value="Pulmonary hypertension"/>
  </concept>
  <concept>
    <code value="202"/>
    <display value="202"/>
    <definition value="Dementia"/>
  </concept>
  <concept>
    <code value="203"/>
    <display value="203"/>
    <definition value="Down syndrome"/>
  </concept>
  <concept>
    <code value="204"/>
    <display value="204"/>
    <definition value="Obesity"/>
  </concept>
  <concept>
    <code value="205"/>
    <display value="205"/>
    <definition value="Thalassemia"/>
  </concept>
  <concept>
    <code value="206"/>
    <display value="206"/>
    <definition value="Cerebrovascular disease"/>
  </concept>
  <concept>
    <code value="207"/>
    <display value="207"/>
    <definition value="Substance use disorder"/>
  </concept>
  <concept>
    <code value="208"/>
    <display value="208"/>
    <definition value="Mental Health conditions"/>
  </concept>
  <concept>
    <code value="209"/>
    <display value="209"/>
    <definition value="History of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus-vectored COVID-19 vaccines"/>
  </concept>
  <concept>
    <code value="210"/>
    <display value="210"/>
    <definition value="Severe allergic reaction after previous dose of Dengue vaccine"/>
  </concept>
  <concept>
    <code value="211"/>
    <display value="211"/>
    <definition value="Evidence of previous dengue infection and living in areas where dengue is endemic"/>
  </concept>
  <concept>
    <code value="212"/>
    <display value="212"/>
    <definition value="Health care personnel involved in the care and transport of patients with suspected or confirmed Ebola virus disease at Special Pathogen Treatment Centers"/>
  </concept>
  <concept>
    <code value="213"/>
    <display value="213"/>
    <definition value="Laboratorians and support staff members at Laboratory Response Network (LRN) facilities that handle specimens that might contain replication-competent Ebola virus in the United States"/>
  </concept>
  <concept>
    <code value="214"/>
    <display value="214"/>
    <definition value="Chronic obstructive pulmonary disease"/>
  </concept>
  <concept>
    <code value="215"/>
    <display value="215"/>
    <definition value="Emphysema"/>
  </concept>
  <concept>
    <code value="216"/>
    <display value="216"/>
    <definition value="Iatrogenic Immunosuppression"/>
  </concept>
  <concept>
    <code value="217"/>
    <display value="217"/>
    <definition value="Persons working in rabies vaccine production facilities"/>
  </concept>
  <concept>
    <code value="218"/>
    <display value="218"/>
    <definition value="Persons performing testing for rabies in diagnostic laboratories"/>
  </concept>
  <concept>
    <code value="219"/>
    <display value="219"/>
    <definition value="Persons who frequently handle bats"/>
  </concept>
  <concept>
    <code value="220"/>
    <display value="220"/>
    <definition value="Persons who frequently have contact with bats"/>
  </concept>
  <concept>
    <code value="221"/>
    <display value="221"/>
    <definition value="Persons who frequently enter high-density bat environments"/>
  </concept>
  <concept>
    <code value="222"/>
    <display value="222"/>
    <definition value="Persons who frequently perform animal necropsies"/>
  </concept>
  <concept>
    <code value="223"/>
    <display value="223"/>
    <definition value="Severe allergic reaction after previous dose of orthopoxvirus vaccine"/>
  </concept>
  <concept>
    <code value="224"/>
    <display value="224"/>
    <definition value="History or presence of atopic dermatitis"/>
  </concept>
  <concept>
    <code value="225"/>
    <display value="225"/>
    <definition value="Household contact with history or presence of atopic dermatitis"/>
  </concept>
  <concept>
    <code value="226"/>
    <display value="226"/>
    <definition value="Active exfoliative skin conditions"/>
  </concept>
  <concept>
    <code value="227"/>
    <display value="227"/>
    <definition value="Household contact with active exfoliative skin conditions"/>
  </concept>
  <concept>
    <code value="228"/>
    <display value="228"/>
    <definition value="Household contact is pregnant"/>
  </concept>
  <concept>
    <code value="229"/>
    <display value="229"/>
    <definition value="Age is less than 1 year"/>
  </concept>
  <concept>
    <code value="230"/>
    <display value="230"/>
    <definition value="Household contact who is less than 1 year of age"/>
  </concept>
  <concept>
    <code value="231"/>
    <display value="231"/>
    <definition value="3 or more known major cardiac risk factors"/>
  </concept>
  <concept>
    <code value="232"/>
    <display value="232"/>
    <definition value="Research laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)"/>
  </concept>
  <concept>
    <code value="233"/>
    <display value="233"/>
    <definition value="Clinical laboratory personnel performing diagnostic testing for more virulent orthopoxviruses (e.g., Variola virus or mpox virus)"/>
  </concept>
  <concept>
    <code value="234"/>
    <display value="234"/>
    <definition value="Designated response team members working with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)"/>
  </concept>
  <concept>
    <code value="235"/>
    <display value="235"/>
    <definition value="Healthcare personnel who care for patients infected with more virulent orthopoxviruses (e.g., Variola virus or mpox virus)"/>
  </concept>
  <concept>
    <code value="236"/>
    <display value="236"/>
    <definition value="Research laboratory personnel working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)"/>
  </concept>
  <concept>
    <code value="237"/>
    <display value="237"/>
    <definition value="Clinical laboratory personnel performing diagnostic testing for less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)"/>
  </concept>
  <concept>
    <code value="238"/>
    <display value="238"/>
    <definition value="Designated response team members working with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)"/>
  </concept>
  <concept>
    <code value="239"/>
    <display value="239"/>
    <definition value="Healthcare personnel who administer ACAM2000"/>
  </concept>
  <concept>
    <code value="240"/>
    <display value="240"/>
    <definition value="Healthcare personnel who care for patients infected with less virulent orthopoxviruses (e.g., Vaccinia virus or Cowpox virus)"/>
  </concept>
  <concept>
    <code value="241"/>
    <display value="241"/>
    <definition value="Known exposure to mpox"/>
  </concept>
  <concept>
    <code value="242"/>
    <display value="242"/>
    <definition value="Presumed exposure to mpox"/>
  </concept>
  <concept>
    <code value="243"/>
    <display value="243"/>
    <definition value="Lack of laboratory confirmation of a previous Dengue infection"/>
  </concept>
  <concept>
    <code value="244"/>
    <display value="244"/>
    <definition value="Severe allergic reaction after previous dose of RSV vaccine"/>
  </concept>
  <concept>
    <code value="245"/>
    <display value="245"/>
    <definition value="American Indian or Alaskan Native"/>
  </concept>
  <concept>
    <code value="246"/>
    <display value="246"/>
    <definition value="Severe immunocompromise"/>
  </concept>
  <concept>
    <code value="247"/>
    <display value="247"/>
    <definition value="Gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following:  1) A new diagnosis of ≥ 1 sexually transmitted disease 2)  More than one sex partner 3)  Sex at a commercial sex venue 4)   Sex in association with a large public event in a geographic area where mpox transmission is occurring"/>
  </concept>
  <concept>
    <code value="248"/>
    <display value="248"/>
    <definition value="Sexual partners of gay, bisexual, and other men who have sex with men, transgender or nonbinary peope who in the past 6 months have had one of the following:  1) A new diagnosis of ≥ 1 sexually transmitted disease 2)  More than one sex partner 3)  Sex at a commercial sex venue 4)   Sex in association with a large public event in a geographic area where mpox transmission is occurring"/>
  </concept>
  <concept>
    <code value="249"/>
    <display value="249"/>
    <definition value="Moving or traveling to an area where TBE is endemic and will have extensive exposure to ticks because of their planned outdoor activities and itinerary"/>
  </concept>
  <concept>
    <code value="250"/>
    <display value="250"/>
    <definition value="Moving or traveling to an area where TBE is endemic who might engage in outdoor activities in areas where ticks are likely to be found"/>
  </concept>
  <concept>
    <code value="251"/>
    <display value="251"/>
    <definition value="Laboratory workers with a potential for exposure to TBE virus"/>
  </concept>
  <concept>
    <code value="252"/>
    <display value="252"/>
    <definition value="Severe allergic reaction after previous dose of Tick-borne Encephalitis vaccine"/>
  </concept>
</CodeSystem>